Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Savolitinib is effective in patients with MET-mutated NSCLC

Savolitinib is effective in patients with MET-mutated NSCLC

Presented by
Dr Shun Lu, Shanghai Chest Hospital, China
Conference
ELCC 2022
Trial
Phase 2
Doi
https://doi.org/10.55788/fbfccb48
    The final results of a phase 2 study confirmed the selective MET tyrosine kinase inhibitor savolitinib to be effective in patients with MET exon 14 skipping-mutated non-small cell lung cancer (NSCLC), irrespective of the subgroup.

    A MET exon 14 skipping mutation is present in about 3% of patients with NSCLC [1]. Savolitinib is a highly selective MET tyrosine kinase inhibitor that is approved in China for the treatment of MET exon 14 skipping-mutated NSCLC based on (interim) results of a phase 2 study (NCT02897479) [2]. Dr Shun Lu (Shanghai Chest Hospital, China) presented the final results of this study [3].

    This multicentre, open-label, phase 2 trial, enrolled 70 patients with unresectable or metastatic MET exon 14 skipping-mutated NSCLC; 25 patients were diagnosed with pulmonary sarcomatoid carcinoma (PSC) and 45 with other types of NSCLC, 28 patients were treatment-naïve and 42 were pre-treated, 15 patients had CNS lesions. Participants were treated with savolitinib 600 or 400 mg once daily, depending on body weight, in 21-day cycles until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR), secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. At data cut-off, 20% of participants were ≥18 months on treatment; median follow-up was 28.4 months.

    Savolitnib demonstrated promising activity in MET exon 14 skipping-mutated NSCLC, regarding both PFS and OS (see Table).

    Table: PFS and OS in subgroups of participants



    With respect to safety, the most common treatment-related adverse events of any grade were peripheral oedema (57%), nausea (53%), hypoalbuminemia (41%), and increased ALT/AST (both 39%). Most common grade ≥3 treatment-related adverse events were increased AST (13%), increased ALT (10%), and peripheral oedema (9%).

    1. Fujino T, et al. Lung Cancer (Auckl). 2021;12:35–50.
    2. Lu S, et al. Abstract 9519. ASCO Annual Meeting 2020, 29–31 May.
    3. Lu S, et al. Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC. Abstract 2MO. ELCC 2022 Virtual Meeting, 30 March–02 April.

     

    Copyright ©2022 Medicom Medical Publishers



    Posted on